XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.07%5.78B | 3.57%1.47B | 5.15%1.46B | 8.58%1.44B | 7.67%1.18B | 4.22%5.45B | 6.04%1.42B | 6.70%1.38B | 2.68%1.33B | -16.06%1.09B |
Total premiums earned | 4.72%4.67B | 4.48%1.18B | 4.76%1.17B | 5.06%1.17B | 4.58%1.15B | 3.38%4.46B | 3.83%1.13B | 3.71%1.12B | 3.13%1.11B | 2.84%1.1B |
Net investment income | 6.64%1.14B | 1.19%282.45M | -15.48%281.28M | 24.31%281.84M | 1,821.28%28.47M | 10.60%1.06B | 15.31%279.14M | 41.52%332.8M | -7.70%226.73M | -100.69%-1.65M |
Net realized gain loss on investments | 67.16%-24.19M | -58.43%2.39M | 102.19%1.49M | 22.38%-8.79M | 19,633.33%3.52M | -54.81%-73.66M | 55.18%5.75M | -286.67%-68.07M | 63.91%-11.33M | 99.22%-18K |
Fee revenue and other income | 14.94%354K | 31.71%162K | -16.00%42K | -12.94%74K | 52.00%76K | -75.28%308K | -67.97%123K | -87.47%50K | -71.57%85K | -69.51%50K |
-Other income expense | 14.94%354K | 31.71%162K | -16.00%42K | -12.94%74K | 52.00%76K | -75.28%308K | -67.97%123K | -87.47%50K | -71.57%85K | -69.51%50K |
Total expenses | 4.66%4.45B | 6.94%1.15B | 1.23%1.08B | 5.28%1.12B | 5.27%862.42M | 3.12%4.25B | 3.91%1.08B | 0.27%1.07B | 4.59%1.06B | -18.76%819.23M |
Loss adjustment expense | 1.05%2.89B | 2.64%738.77M | -4.29%688.18M | 2.53%735.69M | 3.37%731.79M | 1.37%2.86B | 2.49%719.77M | -2.51%719.04M | 3.77%717.51M | 1.98%707.93M |
Policyholder interest | ---- | ---- | ---- | ---- | -4.80%-238.79M | ---- | ---- | ---- | ---- | ---227.85M |
Policy acquisition expense | 7.98%410M | 6.93%104.3M | 8.93%104.31M | 8.33%101.92M | 7.75%99.48M | 8.85%379.7M | 8.22%97.54M | 8.80%95.76M | 9.16%94.08M | 9.26%92.32M |
Fees and commission expense | 6.64%600.75M | 3.20%153.15M | 7.94%149.69M | 8.19%149.8M | 8.00%148.82M | 10.17%563.34M | 14.06%148.4M | 11.15%138.68M | 9.70%138.46M | 9.69%137.8M |
Selling general and administration | ---- | ---- | ---- | ---- | 9.92%89.68M | -0.92%331.9M | -2.14%85.21M | ---- | ---- | -0.02%81.59M |
-General and administrative expense | ---- | ---- | ---- | ---- | 9.92%89.68M | -0.92%331.9M | -2.14%85.21M | ---- | ---- | -0.02%81.59M |
Non-operating net interest income (expenses) | -24.22%-127.09M | -38.96%-35.68M | -20.93%-31.39M | -21.64%-31.4M | -15.10%-28.62M | -13.19%-102.32M | -4.13%-25.68M | -8.30%-25.96M | -18.28%-25.82M | -24.68%-24.87M |
-Interest expense-non operating | 24.22%127.09M | 38.86%35.68M | 20.93%31.39M | 21.64%31.4M | 15.10%28.62M | 13.19%102.32M | 4.21%25.7M | 8.30%25.96M | 18.28%25.82M | 24.68%24.87M |
Special income (charges) | ---- | ---- | ---- | ---- | ---- | 63.94%-900K | ---- | ---- | ---- | ---- |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | -63.94%900K | ---- | ---- | ---- | ---- |
Income before tax | 11.08%1.33B | -7.21%312.43M | 18.24%376.96M | 21.86%322.32M | 14.84%314.92M | 8.36%1.19B | 13.48%336.71M | 35.80%318.82M | -4.32%264.51M | -6.78%274.23M |
Income tax | 14.48%255.88M | -7.55%57.24M | 19.81%73.96M | 29.89%63.97M | 19.92%60.71M | 7.60%223.51M | 13.87%61.91M | 39.70%61.73M | -6.16%49.25M | -10.70%50.62M |
Earnings from equity interest net of tax | ||||||||||
Net income | 10.30%1.07B | -7.13%255.2M | 17.86%302.99M | 20.02%258.36M | 13.69%254.22M | 8.54%970.76M | 13.39%274.8M | 34.89%257.08M | -3.89%215.26M | -5.84%223.61M |
Net Income continuous operations | 10.30%1.07B | -7.13%255.2M | 17.86%302.99M | 20.02%258.36M | 13.69%254.22M | 8.54%970.76M | 13.39%274.8M | 34.89%257.08M | -3.89%215.26M | -5.84%223.61M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 10.30%1.07B | -7.13%255.2M | 17.86%302.99M | 20.02%258.36M | 13.69%254.22M | 8.54%970.76M | 13.39%274.8M | 34.89%257.08M | -3.89%215.26M | -5.84%223.61M |
Preferred stock dividends | ||||||||||
Other preferred stock dividend | ||||||||||
Net income attributable to common stockholders | 10.30%1.07B | -7.13%255.2M | 17.86%302.99M | 20.02%258.36M | 13.69%254.22M | 8.54%970.76M | 13.39%274.8M | 34.89%257.08M | -3.89%215.26M | -5.84%223.61M |
Basic earnings per share | 17.43%11.99 | 4.11%3.04 | 26.84%3.45 | 25.22%2.83 | 16.81%2.71 | 11.83%10.21 | 33.94%2.92 | 38.78%2.72 | -0.88%2.26 | -2.93%2.32 |
Diluted earnings per share | 18.57%11.94 | 4.51%3.01 | 28.36%3.44 | 26.34%2.83 | 17.11%2.67 | 11.39%10.07 | 34.58%2.88 | 38.14%2.68 | -0.88%2.24 | -3.80%2.28 |
Dividend per share | 6.67%0.96 | 6.67%0.24 | 6.67%0.24 | 6.67%0.24 | 6.67%0.24 | 8.43%0.9 | 8.43%0.225 | 8.43%0.225 | 8.43%0.225 | 8.43%0.225 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |